This month we saw changes to three of FDA’s Advisory Committees – the Dermatologic and Ophthalmic Drugs Advisory Committee.
This month we saw changes to three of FDA’s Advisory Committees – the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC), the Nonprescription Drugs Advisory Committee (NDAC), and the Oncologic Drugs Advisory Committee (ODAC).
After quite some time with 11 vacancies, the DODAC saw the addition of 3 new commitee members as of April 17th: Drs. Richard M. Awdeh, Stephen S. Feman, and Mildred M.G. Olivier – all ophthalmologists.
The NDAC saw the departure of their long-time Chair, Richard A. Neill, MD, with current member Ruth M. Parker, MD inheriting the current role of Committee Chair. Dr. Parker has been a member of NDAC since 2011.
For the first time in a while, ODAC now has one vacancy as a result of the departure of Dr. David Steensma. It will be interesting to see who will be his replacement and how long that vacancy will last.
Stay tuned for our mid-month roll call post – spotlight on the Endocrinologic and Metabolic Drugs Advisory Committee!
ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact firstname.lastname@example.org
Interested in learning about ISS’ expert approach to Advisory Committee Meeting preparation? Click below in order to find out for yourself!
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us